Skip to main content
. Author manuscript; available in PMC: 2019 Jun 12.
Published in final edited form as: Lancet Oncol. 2018 Jul 11;19(8):1082–1093. doi: 10.1016/S1470-2045(18)30350-4

Table 4:

Best tumour response per dose in all enrolled patients

Number of patients Complete response plus partial response Disease control (complete response plus partial response plus stable disease)
200 mg/day 3 1 (33%) 1 (33%)
400 mg/day 6 1 (17%) 4 (67%)
600 mg/day 7 2 (29%) 6 (86%)
800 mg/day 15 7 (47%) 14 (93%)

Data are n (%) of patients who achieved a response with differing doses of pazopanib. All patients received pazopanib at the indicated doses plus weekly cetuximab.